Epigenetic modifications as novel therapeutic targets for Huntington's disease

Epigenomics

Volumn 6, Issue 3, 2014, Pages 287-297

  Wang, Fengli ^a,b   Fischhaber, Paula L ^c   Guo, Caixia ^d   Tang, Tie Shan ^a  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d Chinese Academy of Sciences   (China)

Author keywords

5 hydroxymethylcytosine; DNA methylation; epigenetic dysregulation; HDAC inhibitors; histone acetylation; histone methylation; histone ubiquitination; Huntington's disease; therapeutic target; transcriptional dysregulation

Indexed keywords

HISTONE; HISTONE DEACETYLASE INHIBITOR; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ACETYLATION; ANIMAL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; HUMAN; HUNTINGTON DISEASE; METABOLISM; METHYLATION; PATHOLOGY; UBIQUITINATION;

ACETYLATION; ANIMALS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HUNTINGTON DISEASE; METHYLATION; NERVE TISSUE PROTEINS; UBIQUITINATION;

EID: 84905816215     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.19     Document Type: Review

References (99)

1. Vonsattel JPG, Difiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57(5), 369-384 (1998
2. Macdonald ME, Gines S, Gusella JF, Wheeler VC. Huntington's disease. Neuromolecular Med. 4(1-2), 7-20 (2003
3. Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep. 5(10), 958-963 (2004
4. Gutekunst CA, Li SH, Yi H et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 19(7), 2522-2534 (1999
5. Sharp AH, Loev SJ, Schilling G et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14(5), 1065-1074 (1995
6. Rigamonti D, Bauer JH, De-Fraja C et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20(10), 3705-3713 (2000
7. Zuccato C, Ciammola A, Rigamonti D et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293(5529), 493-498 (2001
8. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23(9), 387-392 (2000
9. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33(Suppl.), 245-254 (2003
10. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002
11. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10(7), 457-469 (2010
12. Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447(7143), 425-432 (2007
13. Valor LM, Guiretti D. What's wrong with epigenetics in Huntington's disease? Neuropharmacology 80, 103-114 (2014
14. Stack EC, Del Signore SJ, Luthi-Carter R et al. Modulation of nucleosome dynamics in Huntington's disease. Hum. Mol. Genet. 16(10), 1164-1175 (2007
15. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007
16. Xu Z, Li H, Jin P. Epigenetics-based therapeutics for neurodegenerative disorders. Curr. Transl. Geriatr. Exp. Gerontol. Rep. 1(4), 229-236 (2012
17. Kim MO, Chawla P, Overland RP, Xia E, Sadri-Vakili G, Cha JH. Altered histone monoubiquitylation mediated by mutant huntingtin induces transcriptional dysregulation. J. Neurosci. 28(15), 3947-3957 (2008
18. Ng CW, Yildirim F, Yap YS et al. Extensive changes in DNA methylation are associated with expression of mutant huntingtin. Proc. Natl Acad. Sci. USA 110(6), 2354-2359 (2013
19. Mai A, Massa S, Rotili D et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25(3), 261-309 (2005
20. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 8(1), 57-64 (2008
21. Ferrante RJ, Kubilus JK, Lee J et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23(28), 9418-9427 (2003
22. Gardian G, Browne SE, Choi DK et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280(1), 556-563 (2005
23. Mcfarland KN, Das S, Sun TT et al. Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease. PLoS ONE 7(7), e41423 (2012
24. Yeh HH, Young D, Gelovani JG et al. Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease. Brain Res. 1504, 16-24 (2013
25. Sadri-Vakili G, Bouzou B, Benn CL et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 16(11), 1293-1306 (2007
26. Jiang H, Nucifora FC Jr, Ross CA, Defranco DB. Cell death triggered by polyglutamine-expanded huntingtin in a neuronal cell line is associated with degradation of CREB-binding protein. Hum. Mol. Genet. 12(1), 1-12 (2003
27. Nucifora FC Jr, Sasaki M, Peters MF et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291(5512), 2423-2428 (2001
28. Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl Acad. Sci. USA 96(20), 11404-11409 (1999
29. Steffan JS, Kazantsev A, Spasic-Boskovic O et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97(12), 6763-6768 (2000
30. Cong SY, Pepers BA, Evert BO et al. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol. Cell. Neurosci. 30(1), 12-23 (2005
31. Steffan JS, Bodai L, Pallos J et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413(6857), 739-743 (2001
32. Igarashi S, Morita H, Bennett KM et al. Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport 14(4), 565-568 (2003
33. Anderson AN, Roncaroli F, Hodges A, Deprez M, Turkheimer FE. Chromosomal profiles of gene expression in Huntington's disease. Brain 131(Pt 2), 381-388 (2008
34. Bernstein BE, Birney E, Dunham I, Green ED, Gunter C, Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57-74 (2012
35. Parkel S, Lopez-Atalaya JP, Barco A. Histone H3 lysine methylation in cognition and intellectual disability disorders. Learn Mem. 20(10), 570-579 (2013
36. Lachner M, Jenuwein T. The many faces of histone lysine methylation. Curr. Opin. Cell Biol. 14(3), 286-298 (2002
37. Ng HH, Robert F, Young RA, Struhl K. Targeted recruitment of Set1 histone methylase by elongating Pol II provides a localized mark and memory of recent transcriptional activity. Mol. Cell 11(3), 709-719 (2003
38. Muramoto T, Muller I, Thomas G, Melvin A, Chubb JR. Methylation of H3K4 Is required for inheritance of active transcriptional states. Curr. Biol. 20(5), 397-406 (2010
39. Zhou BO, Zhou JQ. Recent transcription-induced histone H3 lysine 4 (H3K4) methylation inhibits gene reactivation. J. Biol. Chem. 286(40), 34770-34776 (2011
40. Le Martelot G, Canella D, Symul L et al. Genome-wide RNA polymerase II profiles and RNA accumulation reveal kinetics of transcription and associated epigenetic changes during diurnal cycles. PLoS Biol. 10(11), e1001442 (2012
41. Vashishtha M, Ng CW, Yildirim F et al. Targeting H3K4 trimethylation in Huntington disease. Proc. Natl Acad. Sci. USA 110(32), E3027-E3036 (2013
42. Ryu H, Lee J, Hagerty SW et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl Acad. Sci. USA 103(50), 19176-19181 (2006
43. Qiu Z, Norflus F, Singh B et al. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem. 281(24), 16672-16680 (2006
44. Benn CL, Sun T, Sadri-Vakili G et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J. Neurosci. 28(42), 10720-10733 (2008
45. Eustermann S, Yang JC, Law MJ et al. Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin. Nat. Struct. Mol. Biol. 18(7), 777-782 (2011
46. Iwase S, Xiang B, Ghosh S et al. ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome. Nat. Struct. Mol. Biol. 18(7), 769-776 (2011
47. Lee J, Hong YK, Jeon GS et al. ATRX induction by mutant huntingtin via Cdx2 modulates heterochromatin condensation and pathology in Huntington's disease. Cell Death Differ. 19(7), 1109-1116 (2012
48. Sadri-Vakili G, Cha JH. Mechanisms of disease: histone modifications in Huntington's disease. Nat. Clin. Pract. Neurol. 2(6), 330-338 (2006
49. Valor LM, Guiretti D, Lopez-Atalaya JP, Barco A. Genomic landscape of transcriptional and epigenetic dysregulation in early onset polyglutamine disease. J. Neurosci. 33(25), 10471-10482 (2013
50. Wang Z, Zang C, Rosenfeld JA et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat. Genet. 40(7), 897-903 (2008
51. Goldknopf IL, Taylor CW, Baum RM et al. Isolation and characterization of protein A24, a 'histone-like' non-histone chromosomal protein. J. Biol. Chem. 250(18), 7182-7187 (1975
52. Nickel BE, Allis CD, Davie JR. Ubiquitinated histone H2B is preferentially located in transcriptionally active chromatin. Biochemistry 28(3), 958-963 (1989
53. Bett JS, Benn CL, Ryu KY, Kopito RR, Bates GP. The polyubiquitin Ubc gene modulates histone H2A monoubiquitylation in the R6/2 mouse model of Huntington's disease. J. Cell. Mol. Med. 13(8B), 2645-2657 (2009
54. Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl Acad. Sci. USA 103(5), 1412-1417 (2006
55. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 25(10), 1010-1022 (2011
56. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99(3), 247-257 (1999
57. Bestor TH. The DNA methyltransferases of mammals. Hum. Mol. Genet. 9(16), 2395-2402 (2000
58. Jakovcevski M, Akbarian S. Epigenetic mechanisms in neurological disease. Nat. Med. 18(8), 1194-1204 (2012
59. Ma DK, Marchetto MC, Guo JU, Ming GL, Gage FH, Song H. Epigenetic choreographers of neurogenesis in the adult mammalian brain. Nat. Neurosci. 13(11), 1338-1344 (2010
60. Baylin SB, Jones PA. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11(10), 726-734 (2011
61. Wu H, Coskun V, Tao J et al. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 329(5990), 444-448 (2010
62. Hutnick LK, Golshani P, Namihira M et al. DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. Hum. Mol. Genet. 18(15), 2875-2888 (2009
63. Klein CJ, Botuyan MV, Wu Y et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat. Genet. 43(6), 595-600 (2011
64. Winkelmann J, Lin L, Schormair B et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum. Mol. Genet. 21(10), 2205-2210 (2012
65. Psoni S, Sofocleous C, Traeger-Synodinos J, Kitsiou-Tzeli S, Kanavakis E, Fryssira-Kanioura H. MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders. Brain Develop. 34(6), 487-495 (2012
66. Irier HA, Jin P. Dynamics of DNA methylation in aging and Alzheimer's disease. DNA Cell Biol. 31(Suppl. 1), S42-S48 (2012
67. Zajac MS, Pang TY, Wong N et al. Wheel running and environmental enrichment differentially modify exonspecific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus 20(5), 621-636 (2010
68. Watanabe S, Ichimura T, Fujita N et al. Methylated DNAbinding domain 1 and methylpurine-DNA glycosylase link transcriptional repression and DNA repair in chromatin. Proc. Natl Acad. Sci. USA 100(22), 12859-12864 (2003
69. Donkena KV, Young CY, Tindall DJ. Oxidative stress and DNA methylation in prostate cancer. Obstet. Gynecol. Inter. 2010, 302051 (2010
70. Thomas B, Matson S, Chopra V et al. A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Anal. Biochem. 436(2), 112-120 (2013
71. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145(3), 423-434 (2011
72. Wyatt GR, Cohen SS. The bases of the nucleic acids of some bacterial and animal viruses: the occurrence of 5-hydroxymethylcytosine. Biochem. J. 55(5), 774-782 (1953
73. Globisch D, Munzel M, Muller M et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS ONE 5(12), e15367 (2010
74. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324(5929), 929-930 (2009
75. Nestor CE, Ottaviano R, Reddington J et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genom. Res. 22(3), 467-477 (2012
76. Penn NW, Suwalski R, O'Riley C, Bojanowski K, Yura R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem. J. 126(4), 781-790 (1972
77. Song CX, Szulwach KE, Fu Y et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 29(1), 68-72 (2011
78. Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. 38(19), e181 (2010
79. Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930-935 (2009
80. Iyer LM, Tahiliani M, Rao A, Aravind L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle 8(11), 1698-1710 (2009
81. Loenarz C, Schofield CJ. Oxygenase catalyzed 5-methylcytosine hydroxylation. Chem. Biol. 16(6), 580-583 (2009
82. Szulwach KE, Li X, Li Y et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14(12), 1607-1616 (2011).
83. Wang F, Yang Y, Lin X et al. Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease. Hum. Mol. Genet. 22(18), 3641-3653 (2013
84. Chen H, Dzitoyeva S, Manev H. Effect of aging on 5-hydroxymethylcytosine in the mouse hippocampus. Restor. Neurol. Neurosci. 30(3), 237-245 (2012
85. Johnson R, Zuccato C, Belyaev ND, Guest DJ, Cattaneo E, Buckley NJ. A microRNA-based gene dysregulation pathway in Huntington's disease. Neurobiol. Dis. 29(3), 438-445 (2008
86. Lee ST, Chu K, Im WS et al. Altered microRNA regulation in Huntington's disease models. Exp. Neurol. 227(1), 172-179 (2011
87. Lipovich L, Johnson R, Lin CY. MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochim. Biophys. Acta 1799(9), 597-615 (2010
88. Johnson R. Long non-coding RNAs in Huntington's disease neurodegeneration. Neurobiol. Dis. 46(2), 245-254 (2012
89. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coiñ Cancer Cell 22(1), 9-20 (2012
90. Egorin MJ, Yuan ZM, Sentz DL, Plaisance K, Eiseman JL. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother. Pharmacol. 43(6), 445-453 (1999
91. Minamiyama M, Katsuno M, Adachi H et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13(11), 1183-1192 (2004
92. Pallos J, Bodai L, Lukacsovich T et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17(23), 3767-3775 (2008
93. Mielcarek M, Benn CL, Franklin SA et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS ONE 6(11), e27746 (2011
94. Thomas EA, Coppola G, Desplats PA et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA 105(40), 15564-15569 (2008
95. Piekarski M, Jelinska A. Anthracyclines still prove effective in anticancer therapy. Mini Rev. Med. Chem. 13(5), 627-634 (2013
96. Chatterjee S, Zaman K, Ryu H, Conforto A, Ratan RR. Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann. Neurol. 49(3), 345-354 (2001
97. Ferrante RJ, Ryu H, Kubilus JK et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. J. Neurosci. 24(46), 10335-10342 (2004
98. Thaler R, Spitzer S, Karlic H, Klaushofer K, Varga F. DMSO is a strong inducer of DNA hydroxymethylation in preosteoblastic MC3T3-E1 cells. Epigenetics 7(6), 635-651 (2012
99. Yin R, Mao SQ, Zhao B et al. Ascorbic acid enhances Tetmediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J. Am. Chem. Soc. 135(28), 10396-10403 (2013).